China's Spiritual Economy Is Booming as Gen Z Turns to Tarot
At a dimly lit bar in Beijing, the rattle of wooden sticks used for fortune telling blends with the clink of cocktail glasses. Patrons here aren't just ordering drinks — they seek a glimpse into the future.
These hybrid venues — where mixology meets mysticism — are cropping up across Chinese cities, offering drinks alongside tarot readings and other means of divining whatever is to come. It's part of a broader boom in what analysts are calling China's Xuanxue, or metaphysical, economy — an expanding sector that includes astrology, tarot and crystal healing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
20 minutes ago
- Associated Press
SINOVAC Board of Directors Prevails Against Advantech/Prime's New York Lawsuit
BEIJING--(BUSINESS WIRE)--Jun 20, 2025-- SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success' ('Advantech/Prime') Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York. The result in the New York court represents another failure in the campaign by Advantech/Prime in coordination with Vivo Capital (together known as the 'Dissenting Investor Group') to wrest control of SINOVAC from its recently installed, lawfully-elected Board of Directors (the 'current SINOVAC Board') in accordance with the Privy Council order and Antiguan Law, and to interfere with the payment of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board. Following the New York court's ruling, the current SINOVAC Board is free to pursue its legal action in Antigua seeking to cancel the PIPE shares invalidly issued to the Dissenting Investor Group by the former illegitimate board (the 'Imposter Former Board'). If the current SINOVAC Board succeeds in legal proceedings on the PIPE shares, it has announced its intention to redistribute an additional US$11.00 per common share to SINOVAC's valid shareholders. Dr. Chiang Li, Chairman of the SINOVAC Board, commented, 'We will continue our mission to restore fairness and deliver value to all valid SINOVAC shareholders, starting with paying the $55.00 per share special cash dividend as soon as July 7, 2025.' The Dissenting Investor Group's self-serving, multi-pronged lawfare strategy against SINOVAC has one goal: to prevent all valid SINOVAC common shareholders from receiving any dividend payments unless the Dissenting Investor Group receives an allocation for their invalid PIPE shares, despite the fact that they have already received over US$1 billion in dividends from a SINOVAC operating subsidiary. The current SINOVAC Board has set aside in escrow the pro rata portion of dividends for the PIPE shares — funds the Dissenting Investor Group could receive if the legal proceedings they initiated rule in their favor. The current SINOVAC Board is fighting back – and winning. We feel certain that we will prevail against any further legal action by the Dissenting Investor Group and look forward to ensuring all valid shareholders receive their fair share. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at [email protected]. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at [email protected]. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on CONTACT: Investor and Media Contact FGS Global [email protected] KEYWORD: CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC NEW YORK INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: The Board of Directors of Sinovac Biotech Ltd. Copyright Business Wire 2025. PUB: 06/20/2025 10:56 PM/DISC: 06/20/2025 10:55 PM
Yahoo
2 hours ago
- Yahoo
Your Daily Work Horoscope for June 21, 2025
Your Daily Work Horoscope for June 21, 2025. Discover your Daily Work Horoscope for each zodiac sign here. Try to get a private meeting with a boss, coworker, or client you need to reach. It's not easy to speak about feelings at work, but now's the time. They'll perk up and listen. Your feelings are running a little too deep now, and you can't trust what your gut says. Use your head when big deals come your way, and postpone final decisions until later if necessary. You have all the info you need now, whether you know it or not. Now is the time to make that decision that will guide the direction of your career. You may not get a chance like this again! You're usually pretty gregarious, but now you're feeling a strong urge to hole up at your desk. Public contact will be slow going. Even so, you can make a lot of progress on your own. Inventory and assets should be on your mind now. It's a good time to recheck stocks and reconsider how you're using what you have. Cash flow isn't be a problem, but it can be improved. Need guidance? Your Numerology Reading is a mystic cheat-sheet to living your full potential. If you're not in a leadership position yet, people will start to wonder why after today. Your vision will garner you some extra respect, and might just get you noticed by the powers that be. You can see what's going on under the surface more clearly than usual, and you will be able to use that insight to help build (or rebuild) morale. Help your teammates see what they need to see. Your instincts and emotions will help drive your work today, but make sure you set realistic goals for yourself. Later, you might have to revise them just a bit, but you'll still make great progress. Wavering over a decision? That's an excellent sign to delay anything final for the time being. Hold off until new information comes in. It might be as soon as tomorrow or as long as a few weeks. No amount of preparation can help you deal with the day's events, but your innate flexibility will make the difference between success and failure. Watch carefully and react appropriately. You won't be entirely comfortable for much of the day, but that's because your energy banks are refilling and the buzz is a little distracting. Soon you'll be back in the game and full of zip. Territory issues leave you moody, but you can turn that energy into some serious productivity if you lay off the infighting and drama and throw yourself back into strengthening your position. Find your cosmic purpose. Receive personalized astrological guidance with Astrology+.
Yahoo
2 hours ago
- Yahoo
Huawei Patents Solid-State Battery That Would Let You Road Trip From Miami To Maine On A Single Charge
Toyota is currently working on solid-state batteries it says will allow it to build 900-mile EVs, but while many would call that overkill, dads across the country know it isn't enough. We need more range if EVs are ever going to be good enough for a proper road trip, and if Huawei can deliver on its latest solid-state battery patent, we may almost be there. That's because it offers more than 1,800 miles of range on a single charge, CarNewsChina reports. For context, that's enough range to drive from Miami, Florida, to Bangor, Maine, without stopping. That said, China's range estimates are even more generous than Europe's, which means you may only get 1,200 or 1,300 miles out of a battery like that in the United States. Pitiful, I know. At that point, there's basically no reason to even bring your external catheter on a road trip. Not that the U.S. would allow Chinese battery tech to be sold here in the first place or invest in catching up. Our EV tech will stay generations behind China's, and we will like it. From the sound of it, the real value in this patent is the battery's energy density: The patent outlines a solid-state battery architecture with energy densities between 400 and 500 Wh/kg, potentially two to three times that of conventional lithium-ion cells. The filing also details a novel approach to improving electrochemical stability: doping sulfide electrolytes with nitrogen to address side reactions at the lithium interface, a long-standing obstacle to the commercialisation of sulfide-based batteries. Huawei's design aims to boost safety and cycle life by mitigating degradation at this critical junction. Read more: These Supercars Lose Value So Quickly, They're Almost A Steal Allegedly, given a big enough charger, Huawei says it could charge the battery in about five minutes, too. That would require an absolutely absurd amount of power, but it isn't like companies in China aren't working on that, too. BYD has already shown off a Megawatt charger that's capable of adding 250 miles of range in about five minutes. Early versions would also likely cost a small fortune, though, and it's also hard to see how practical Megawatt charging would be in the remote areas where people might actually use it. But while BYD does actually plan to build at least some of those Megawatt chargers, don't be surprised if Huawei's 1,800-mile solid-state battery ends up being more of a tech demonstration than anything else. Instead, it seems much more likely that the batteries that will ultimately make their way into production cars will be smaller and therefore lighter. A battery that's a third the size of the 1,800-mile battery would still offer more than enough range for a road trip while also drastically reducing weight. Considering how heavy EV batteries are — the battery in the Hummer EV weighs nearly 3,000 pounds — if there's one thing EVs need, it's less weight. So while Huawei's 1,800-mile battery is still theoretical for now, it's still cool to see battery tech advancing to the point where, in a few years, we may see long-range EVs that weigh about the same as gas-powered cars. At least in other countries outside the U.S., since Republicans have decided they'd rather just turn us into a technological backwater. Want more like this? Join the Jalopnik newsletter to get the latest auto news sent straight to your inbox... Read the original article on Jalopnik.
